Abstract
The role of regional lymph nodes in melanoma metastasis has long been recognized. This review will detail the evolving role of sentinel lymph node biopsy (SLNB) in melanoma management in the era of adjuvant therapies. We analyze key themes and findings from recent publications, highlighting both areas of consensus and ongoing controversies. While the landscape of melanoma management continues to evolve with the advent of novel therapeutic combinations, SLNB remains a valuable tool for staging and potentially provides therapeutic benefit. However, optimal patient selection for SLNB requires careful consideration of individual risk factors and benefits of adjuvant therapy.